Showing 141-150 of 7575 results for "".
FDA Approvals, Acne Insights, EPI Gets Cloderm
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approvals-acne-insights-epi-gets-cloderm/18230/In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US mayMeeting Recap: Aesthetic Extenders Symposium 2018
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/meeting-recap-aesthetic-extenders-symposium-2018/18234/Faculty and industry partners discuss the highlights of the Aesthetic Extenders Symposium. From novel uses of toxins to skincare and injections techniques, AES provided a range of updates. AES 2019 will be held in Miami, FL.Altreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobNatural Products that Exhibit Antifungal Activity
https://practicaldermatology.com/topics/general-topics/natural-products-that-exhibit-antifungal-activity/20360/Can natural products fight the fungus among us?Four Ways to Ease the Burden of Prior Authorization
https://practicaldermatology.com/topics/practice-management/four-ways-to-ease-the-burden-of-prior-authorization/20434/There's no way around PAs, but it is possible to make the process more manageable.Shielding Personal and Practice Assets
https://practicaldermatology.com/topics/practice-management/shielding-personal-and-practice-assets/20491/All tools are not equal when it comes to protecting assets.Allergan's Cool Campaign, Obagi Line Launches, Apple Upgrades Health App
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-s-cool-campaign-obagi-line-launches-apple-upgrades-health-app/18346/There's some misleading information about fat reduction out there, and that's not cool, Allergan says. The company's CoolSculpting device has launched the “Not Cool Vs. Cool” campaign. Data show patients and doctors assess scars differently: Patients tend to focus on scar depth, while physicians focTwo Launches from Cutera, AmSpa Projections
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-two-launches-from-cutera-amspa-projections/18356/Cutera introduces two new devices to its laser and energy-based device offerings: Juliet laser represents Cutera's first entry into the women's health segment of the aesthetics market; Secret RF is a new fractional radio frequency microneedling device that effectively remodels collagen, improves milThe Year in Aesthetics
https://practicaldermatology.com/topics/practice-management/the-year-in-aesthetics/20399/A look at innovations and approvals in cosmetic dermatology in 2017.Janssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or active